🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise around the world, with data suggesting in excess of 82 million instances per year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, the spread of superbugs and the very limited treatment choices presently on offer.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

According to results released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to license and sell the drug in numerous developing nations.

Clinicians directly involved have shared positive views. Access to a one-pill regimen such as this is seen as a "revolutionary step" for public health efforts. This is viewed as crucial to lessen the impact of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.